Metabolic & Incretin Research blend
Retatrutide + Tirzepatide RT+TR
Triple + dual incretin blend
Research blend of retatrutide, a GIP, GLP-1 and glucagon triple agonist, and tirzepatide, a GIP and GLP-1 dual agonist.
Evidence level. Little or no public data, or the exact identity is still being confirmed. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- Triple + dual incretin blend
- Category
- Metabolic & Incretin
- Type
- Research blend
- Abbreviation
- RT+TR
- Development and regulatory status
- Combination not approved; tirzepatide approved alone, retatrutide investigational
Blend composition
Retatrutide 20 mg + Tirzepatide 40 mg (10 ml)
Each component is profiled separately in the catalogue: Retatrutide, Tirzepatide.
What researchers study
A research blend of retatrutide, a GIP/GLP-1/glucagon triple agonist, and tirzepatide, a GIP/GLP-1 dual agonist. Both act on incretin receptors, so the pairing is of interest for comparing overlapping receptor pharmacology.
Research areas
- Comparing triple and dual incretin agonist pharmacology
- Overlapping GIP and GLP-1 receptor signalling
- Glucagon-receptor contribution to energy balance in models
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- literature check
No published studies of this specific retatrutide plus tirzepatide combination were identified
- phase 2 trial
Retatrutide alone: mean weight change at 48 weeks was -24.2% in the highest-dose group versus -2.1% with placebo, in 338 adults
- phase 3 trial
Tirzepatide alone: mean weight change at 72 weeks ranged from -15% to -20.9% across dose groups versus -3.1% with placebo in 2,539 adults
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Retatrutidetriple GIP/GLP-1/glucagon agonist, a component of this blend
- Tirzepatidedual GIP/GLP-1 agonist, a component of this blend
